Lymphoma

Updated phase 1/1b BGB-11417-101 trial data showed sonrotoclax 320 mg plus zanubrutinib achieved uMRD4 rates exceeding 90% in treatment-naive CLL/SLL.

Emmanuel Bachy, MD, PhD, highlighted high efficacy, durable responses, and a favorable adverse effect profile in follicular lymphoma with high tumor burden.

The safety profile of the CAR T-cell product in the real world was consistent with that observed in the TRANSCEND MCL study.

No new safety signals were observed with the LAG-3 inhibitor-based therapy among patients with relapsed/refractory classic Hodgkin lymphoma.

The brentuximab vedotin-based regimen was consistently favored in sensitivity analyses regardless of covariate adjustment tested.

The use of CD20×CD3 bispecific antibodies correlated with lower hematologic toxicity, higher responses, and preserved CAR T fitness in LBCL groups.

The phase 3 EPCORE DLBCL-1 data showed epcoritamab reduced progression or death risk by 26% vs chemoimmunotherapy in relapsed/refractory LBCL.

There was no clear prognostic impact of age, comorbidities, complex living skills, or basic self-care tasks on PFS for diffuse large B-cell lymphoma.

The addition of epcoritamab to lenalidomide and rituximab showed improved efficacy and manageable safety in relapsed/refractory follicular lymphoma.

Adverse drug reactions occurred in 1 patient treated with VT-EBV-N, although no grade 3 or higher events emerged.

Support for the NMPA approval of rocbrutinib in relapsed/refractory mantle cell lymphoma was based on findings from the phase 2 ROCK-1 trial.

No dose-limiting toxicities, TEAE-related discontinuations, or deaths were observed in this pretreated lymphoma population.

In those with centrally confirmed lymphoma subtypes, the HR for PFS was 0.68, with a 24-month PFS rate of 72.7% vs 62.2% in favor of the tafasitamab combo.

Matthew Matasar, MD, of Rutgers Cancer Institute, spoke about upcoming trials in lymphoma to look out for at the ASCO 2026 Meeting.

Orelabrutinib is now available in Australia for patients with relapsed/refractory mantle cell lymphoma.

Clinician-rated toxicities appear to consistently underreport severity compared with patient-reported outcomes in this lymphoma population.

Hua-Jay Cherng, MD, explored how ctDNA and MRD are shifting from theoretical markers to actionable clinical tools in DLBCL.

Phase 1/2 findings from the BGB-11417-201 trial support the FDA approval of sonrotoclax in relapsed/refractory mantle cell lymphoma.

Steven M. Horwitz, MD, discussed the PRIMO dosing strategy to manage adverse effects in lymphoma.

Jennifer Effie Amengual, MD, discussed using epigenetic drugs to enhance immune surveillance and other novel lymphoma therapeutic strategies.

Craig H. Moskowitz, MD, discussed the transition toward molecularly defined lymphoma care and the declining role of autologous stem cell transplantation.

Hematologic oncologists discussed long-term survival data from the SEQUOIA and ALPINE trials exploring zanubrutinib in frontline and R/R CLL/SLL.

A data monitoring committee recommended the halt for futility of the phase 3 FLASH2 trial evaluating synthetic hypericin in cutaneous T-cell lymphoma.

A total of 48.0% of patients treated with duvelisib experienced a response, 33.3% of whom experienced a complete response.